TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Spinal Cord Stimulation in Hypotensive Heart Failure Patients: Hemodynamic Assessment

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Age 18-75 years.~2. Patients with heart failure III-IV functional class (NYHA) with indications to right heart catheterization.~3. Systolic blood pressure \<110/70 mm Hg when measured while sitting.~4. Patient who signed an informed consent form.~Exclusion Criteria:~1. Hypovolemic status (central venous pressure \<2 mm Hg).~2. Any acute illness.~3. Transient ischemic event or stroke within 2 weeks prior to inclusion.~4. Pulmonary embolism \<1 month ago.~5. Epilepsy.~6. An implanted infusion pump.~7. Pacemaker-dependent patients.~8. Patients who have contraindications to the use of the patch electrodes used in this study, as indicated in the respective instructions for use.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Spinal cord stimulation in heart failure patients with hypotension (Type: EXPERIMENTAL): Adhesive patches are applied to subjects' back skin. Single stimuli are delivered in order to define the stimulation threshold under the guidance of neuromyography. Vascular access is performed (jugular or subclavian) according to conventional preparation to right heart catheterization. Invasive hemodynamic measures are performed as usual.~High-frequency spinal cord stimulation at T5 level is initiated, and repeated hemodynamic measures performed within 2 minutes. Stimulation lasts for 5-10 minutes, and then ceased. Following a 5-minutes waiting period, repeat hemodynamic measures are performed. The same sequence of steps applies for stimulation levels T7-8 and a combination of T5 and T7-8.~Then the procedure is completed and data are analysed.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Correlation of Peak Tidal Inspiratory Flow Measured Before and After Extubation in Adult Patients With Hypoxemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Adult intubated patients aged between 18 to 90 years~* Pass spontaneous breathing trial and receive the order to be extubated~* Have at least one of the indications to use HFNC after extubation~Exclusion Criteria:~* Need to use inhaled epoprostenol via HFNC~* Pregnant~* Unable to use resuscitation mask, such as facial trauma, claustrophobia~* Non-English speaker~* Inability to verbally communicate~* Using extracorporeal membrane oxygenation (ECMO)~* Hemodynamically unstable~* Difficult airway

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- HFNC flow set at 1.33 times of patient peak tidal inspiratory flow (Type: EXPERIMENTAL): HFNC flow will be set at the level that is 1.33 times of patient peak tidal inspiratory flow
- HFNC flow set at 1.67 times of patient peak tidal inspiratory flow (Type: EXPERIMENTAL): HFNC flow will be set at the level that is 1.67 times of patient peak tidal inspiratory flow
- HFNC flow set at 2 times of patient peak tidal inspiratory flow (Type: EXPERIMENTAL): HFNC flow will be set at the level that is 2 times of patient peak tidal inspiratory flow
- HFNC flow set at patient peak tidal inspiratory flow (Type: ACTIVE_COMPARATOR): HFNC flow will be set at the level that matches patient peak tidal inspiratory flow

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Ursodeoxycholic Acid in C. Difficile Infection

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Completion of a course of antibiotic treatment for C. difficile infection within the previous 7 days~Exclusion Criteria:~* • Pregnant or Breast-feeding~  * Gall bladder inflammation~ * Frequent episodes of biliary colic~ * Occlusion of the common bile duct or cystic duct~ * Active small intestinal inflammation~ * Previous resection of distal small intestine~ * Treatment with bile salt binding agents, ciclosporin or ciprofloxacin~ * Diarrhoea (from any cause) at study initiation~ * hypersensitivity to bile acids or any excipient of the formulation~ * Life expectancy less than 6 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ursodeoxycholic acid (Type: EXPERIMENTAL): Only one arm - subjects receiving ursodeoxycholic acid

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Video Capsule Endoscopy Versus Colonoscopy in Patients With Melena and Negative Upper Endoscopy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~• Inpatients \>18 years of age presenting with lower gastrointestinal bleeding and have melenic stool~Exclusion Criteria:~* Unable to provide written informed consent~* A probable bleeding source is identified on upper endoscopy~* Pregnancy or lactation~* Swallowing Disorder~* Unable to tolerate sedation or anesthesia due to medical co-morbidities~* Uncorrected coagulopathy (platelet count \<50,000, INR\> 2, PTT\> 2x upper limit of normal)~* Known or suspected gastrointestinal obstruction or stricture~* Cardiac pacemaker or other implanted electromedical device~* Contraindication to bowel preparation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Video Capsule Endoscopy (Type: ACTIVE_COMPARATOR): Randomization arm one is to video capsule endoscopy (VCE) a non-invasive procedure in which a patient swallows a disposable 1.0 X 2.5 cm 'pill' containing a camera electronically linked to equipment outside the patient which records images as it passes from the esophagus through the entire tract and is excreted in feces. It images the small intestine in areas beyond the reach of upper GI endoscopy and the terminal ileum and is similarly beyond the reach of colonoscopy. Its greatest use is in identifying points of bleeding and ulcers.
- Next Day Colonoscopy (Type: ACTIVE_COMPARATOR): Randomization arm two is to colonoscopy, a test that allows the doctor to look at the inner lining of the large intestine (rectum and colon). He or she uses a thin, flexible tube called a colonoscope to look at the colon.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Pre-ESRD Syndrome in High Risk African Americans

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria: 18-35, healthy volunteers, African American~Exclusion Criteria: Active medical conditions, prescription drug therapy other than birth control

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 35 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the Adherence and the Patient Acceptability of Zomacton® Treatment With the Zomajet® Vision X Device

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patient with growth hormone deficiency,~  1. Diagnosis of growth hormone deficiency proven by appropriate exploration~ 2. Size ≤ -2 Standard Deviation (SD) according to the French references~ 3. Growth velocity in the previous year inferior to the normal for age (-1SD) or \< 4cm/year~* Growth deficiency due to Turner's syndrome~  1. Turner's syndrome confirmed by a karyotype~ 2. Patient's size ≤ -2 SD according to the French references~ 3. Bone age \< 12 years~* Patient who require a minimum of 18 months of treatment.~Exclusion Criteria:~* There are no exclusion criteria except the contraindication for Zomacton® 10 mg

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Zomacton® treatment with Zomajet® Vision X device (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Necessity of Antibiotics for Prevention of Delivery-associated Infections After Spontaneous Vaginal Delivery at Term

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Term pregnancy~* Normal labor~Exclusion Criteria:~* Penicillin allergy~* Previous history antibiotic using within 2 weeks~* Patients cannot take oral medication~* Patients have underlying disease eg. diabetes mellitus, hypertension, HIV infection~* Premature rupture of membranes

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Amoxicillin (Type: EXPERIMENTAL): The patient will be received amoxicillin 500 mg 2 capsules orally bid pc for 5 days
- Placebo (Type: PLACEBO_COMPARATOR): The patient will be received placebo 2 capsules orally bid pc for 5 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Peri-operative Expression Analysis of Pancreatic Stone Protein in a Surgical Study Population

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion criteria: - \>= 18 years~* abdominal major surgery~* need for post-operative ICU care~Exclusion criteria: - \<18 years~- patients who do not agree the written informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Sepsis Group (Type: None): Patients suffering from sepsis in the postoperative course after major abdominal surgery
- Control Group (Type: None): Patients without suffering sepsis during postoperative follow up after major abdominal surgery

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Neurophysiological Validation of the Clinical Criteria of Sensitization in Chronic Pelvic and Perineal Pain Population

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Women \> 25 years,~* Pelvic or perineal pain since \> 3 months,~* No injury in pelvic imagery or clinical examination that may explain all the pain complaint,~* Patient who can understand the protocol,~* Patient who agreed and signed the informed consent for participation.~Exclusion Criteria:~* Poor understanding of French language,~* Pregnancy or lactation,~* Severe depression (Beck Depression Inventory-Short form \> 16),~* Initial pain estimation at 10 on numeric analog scale,~* Inadequately cooperating,~* Isolated dysmenorrhea,~* Deep endometriosis with rectal or bladder lesion,~* Genital or bladder infection,~* Urogenital tumor history,~* Anorectal surgery history a type of digestive resection,~* Anal stenosis,~* Advanced vaginal prolapse (stage 2 on POP-Q scale),~* Post-traumatic stress disorder history,~* Deprived of liberty (trusteeship, guardianship).

- Gender: FEMALE
- Minimum Age: 25 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Patient with pelvic or perineal pain with sensitization (Type: OTHER): Patients with chronic pelvic or perineal pain with sensitization (Convergences PP criteria \> 5)
- Patient with pelvic or perineal pain without sensitization (Type: OTHER): Patients with chronic pelvic or perineal pain without sensitization (Convergences PP criteria \< 5)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Desmopressin for Bedwetting in Children With SCD

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients with Hemoglobin SS, SC, SB0thal or SB+thal~2. Patients with at least two episodes of primary nocturnal enuresis per week or four episodes over the two weeks prior to enrollment.~3. Patients with secondary enuresis who have been evaluated and cleared by a pediatric urologist as not having other etiologies of enuresis (e.g. overactive detrusor activity, a genitourinary anatomic abnormality)~Exclusion Criteria:~1. Patients with developmental delay or neurologic dysfunction secondary to stroke.~2. Patients with hypertension or underlying renal disease.~3. Patients with genitourinary anatomic abnormalities. Any prior renal ultrasound showing normal genitourinary anatomy is sufficient to clear a patient for the study.~4. Patients with daytime urinary incontinence~5. Patients with glucosuria on urinalysis.~6. Patients with secondary nocturnal enuresis who have not been evaluated by a pediatric urologist to rule out other etiologies of enuresis.~7. Patients who are pregnant.~8. Patients receiving another medicine for nocturnal enuresis (e.g. imipramine).

- Gender: ALL
- Minimum Age: 8 Years
- Maximum Age: 21 Years
- Healthy Volunteers: f

Study Arms:
- Treatment Group (Type: EXPERIMENTAL): Desmopressin 0.2mg tablets, dose titrated to effect

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study of the Intravitreal Implantation of NT-503-3 Encapsulated Cell Technology (ECT) for the Treatment of Recurrent Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Diagnosis of Active (recurrent or persistent) subfoveal CNV lesions secondary to AMD in the study eye~* Prior Intravitreal Anti-VEGF injections~Key Exclusion Criteria:~* Significant subretinal hemorrhage~* Significant Scar and/or, fibrosis~* Suspected polypoidal choroidopathy, or pigment epithelial tears or rips~* Inadequate response to anti-VEGF therapy

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- NT-503-3 ECT implantation (Type: EXPERIMENTAL): None
- Eylea® injected intravitreally every 8 weeks (Type: ACTIVE_COMPARATOR): Eylea® injected intravitreally every 8 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Use and Safety of the LUTONIX® Drug Coated Balloon Catheter in Arteries of the Lower Extremity

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. ≥ 18 years of age;~2. Rutherford Clinical Category ≤ 5;~3. Patient or Legally Authorized Representative is willing to provide informed consent and comply with the required follow up;~4. Stenotic or obstructive vascular lesions in artery(s) of the lower extremity;~5. Lesion(s) can be treated with available LUTONIX Drug Coated Balloon Catheter device size matrix per current country-specific IFU.~Exclusion Criteria:~1. Patient is currently participating in an active phase of another investigational drug or device study;~2. Inability to take recommended medications as stated in the IFU or non-controllable allergy to contrast.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Single Arm: Lutonix Drug Coated Balloon (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Phase III, Multi-Centre, Randomised, Placebo-Controlled Study in Combination With Ca-based P Binders in Patients With Hyperphosphatemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female, 18 to 80 years of age.~2. Stable phosphate control using Calcium-based phosphate-binding medication only.~3. The subject is undergoing regular dialysis treatment.~4. On a stabilised phosphorus diet.~5. If female and of child-bearing potential, has a negative serum pregnancy test. Sexually active females must agree to take appropriate steps not to become pregnant.~6. Male subjects must agree to use appropriate contraception.~Exclusion Criteria:~1. Current clinically significant medical comorbidities, which may substantially compromise subject safety, or expose them to undue risk, or interfere significantly with study procedures and which, in the opinion of the Investigator, makes the subject unsuitable for inclusion in the study.~2. Body mass index (BMI) \<=16.0 kg/m2 or =\>40.0 kg/m2.~3. Current or a history of significant gastrointestinal motility problems~4. A positive test for hepatitis B surface antigen, hepatitis C antibody or HIV 1 and 2 antibodies.~5. A history of substance or alcohol abuse within the last year.~6. Seizure disorders.~7. Using phosphate binder medication other than calcium based phosphate binders~8. Using colestyramine, colestipol or colesevelam~9. A history of drug or other allergy~10. Participated in a clinical study with any experimental medication in the last 30 days or an experimental biological product within the last 90 days, prior to signing of the informed consent.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: PLACEBO_COMPARATOR): None
- 2 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: CORE: Study to Evaluate the Conducted AF-Response-Algorithm in Patients Suffering From Heart Failure and Atrial Fibrillation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Implant of a Medtronic InSync III Marquis (7279) or later system with Conducted AF-Response~Exclusion Criteria:~* Medical reasons that are adverse to participation in the study and compliance by the patient~* Patients who are enrolled in another study or plan to be enrolled into another study~* Pregnant patients or patients who are possibly pregnant due to an unreliable form of contraception

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Conducted AF-Response Algorithm (CAFR) On (Type: EXPERIMENTAL): CAFR: On~* Level medium~* Max. Rate: 110ppm VSR: Off
- Conducted AF-Response Algorithm (CAFR) Off (Type: ACTIVE_COMPARATOR): CAFR: Off VSR: Off

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: vMII for Measurement of Oesophageal Bolus Transport and Reflux

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* male or female~* at least 18 years of age~* have given informed consent for the vMII and Barium videofluoroscopy~* have symptoms of reflux, dysphagia, have known achalasia or are planned for anti-reflux surgery~Exclusion Criteria:~* with medications influencing gastrointestinal function within 3 days of the study~* with those on anticoagulants~* with any hematological abnormalities~* with any evidence of infectious disease~* who are pregnant or breast-feeding or sexually active and not on contraception.~* with evidence or history of drug or alcohol abuse within the past two years~* with diabetes mellitus~* with severe physical or mental health concerns on screening which may contribute to the ability to comply with study requirements~* with active co-morbid conditions~* with oesophageal surgery or stent (dilation acceptable)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Achalasia (Type: EXPERIMENTAL): Long vs Short Myotomy repair of Achalasia
- Dysphagia control (Type: EXPERIMENTAL): Conservative Management
- GORD for surgery (Type: EXPERIMENTAL): Partial vs Full Fundoplication repair
- GORD not for surgery (Type: EXPERIMENTAL): esomeprazole 40 mg vs no esomeprazole

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility